This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "Amosulalol" – news · newspapers · books · scholar · JSTOR (November 2023) (Learn how and when to remove this template message)

Amosulalol
Clinical data

AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name (RS)-5-[1-hydroxy-2-[2-(2-methoxyphenoxy)ethylamino]ethyl]-2-methylbenzenesulfonamide
CAS Number	85320-68-9^Y
PubChem CID	2169
ChemSpider	2084^Y
UNII	C69JI1BAU8
KEGG	D07451^Y
ChEMBL	ChEMBL152231^Y
Chemical and physical data
Formula	C₁₈H₂₄N₂O₅S
Molar mass	380.46 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=C(C=C(C=C1)C(CNCCOC2=CC=CC=C2OC)O)S(=O)(=O)N
InChI InChI=1S/C18H24N2O5S/c1-13-7-8-14(11-18(13)26(19,22)23)15(21)12-20-9-10-25-17-6-4-3-5-16(17)24-2/h3-8,11,15,20-21H,9-10,12H2,1-2H3,(H2,19,22,23)^Y Key:LVEXHFZHOIWIIP-UHFFFAOYSA-N^Y
(verify)

Amosulalol (INN) is an antihypertensive drug. It has much higher affinity for α₁-adrenergic receptors than for β-adrenergic receptors.^[1] It is not approved for use in the United States.

References

^ Sponer G, Bartsch W, Hooper RG (1990). "Drugs acting on multiple receptors: β-blockers with additional properties.". Pharmacology of antihypertensive therapeutics. Handbook of Experimental Pharmacology. Vol. 93. Berlin, Heidelberg: Springer. pp. 131–226 (183). doi:10.1007/978-3-642-74209-5_5. ISBN 978-3-642-74209-5.